null

null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-revenue-positive medtech; raised ~$240M+ in equity; modest debt, likely net cash position post-Series E/F rounds reducing leverage sensitivity

Equity-funded growth-stage company; rising rates increase cost of future capital raises and pressure valuation multiples on DCF basis significantly

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

TSMC/Taiwan semiconductor fabs for compute hardware; AWS US-East infrastructure concentration as primary cloud dependency

EU (EUR), UK (GBP), Japan (JPY) are top international markets; EUR/USD and GBP/USD volatility directly compress reimbursement-denominated revenue

~70% US revenue; EU and UK represent meaningful share; JPY and GBP devaluation risk moderate given limited Japan penetration currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

AWS likely represents non-substitutable infrastructure layer; FDA-cleared AI pipeline tightly coupled to specific cloud compute environment

Cloud-native SaaS/analytics; AWS termination would cause 30-day critical outage requiring 6-12 month migration, disrupting hospital integrations

Per-analysis fee model layered on SaaS; cloud dependency makes secondary on-premise fallback implausible within short notice window

High API coupling to hospital EHR/PACS systems (Epic, GE); re-integration costs and FDA re-clearance risk creates strong clinical workflow lock-in

Revenue from per-analysis fees and hospital contracts; no investment contract or profit-sharing structure—Howey Test risk is negligible, near zero

Very High

High GDPR exposure: cardiac CT DICOM data processed cross-border; CCPA applies to California patients; DPA agreements and data residency controls required

Low near-term antitrust risk; niche FFR-CT market with Siemens/GE as indirect competitors; potential concern if hospital system exclusivity clauses expand

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly per-analysis transactional fees (~60-70%) with growing multi-year hospital enterprise contracts (~30-40% recurring); transitioning toward subscription

Per-analysis fee (~$1,000-$1,500 per HeartFlow FFRCT analysis) billed to hospitals/payers; volume-tiered enterprise contracts for high-volume centers

Per-unit pricing vulnerable to payer reimbursement rate cuts (CMS/CPT code dependency); bundled payment models could compress per-analysis realization

Moderate-high; sole FDA-cleared noninvasive FFRCT platform with strong clinical evidence base, but reimbursement rates set externally by CMS/payers

76.8% Gross Margin (Premium (>60%))

No meaningful free-rider problem; paid per-analysis model with clinical workflow integration; churn risk from budget freezes or competing modalities

Sublinear growth model; AI analysis is automated, marginal cost per additional scan is near-zero compute cost; commercial/support headcount scales modestly

Near-zero marginal cost per additional FFR-CT analysis after fixed R&D/infrastructure; revenue doubling requires <20% headcount increase—highly scalable

null

At 10x scale, CAC likely declines via network referrals; LTV:CAC improves as per-analysis volume per hospital site compounds; sales cycle remains 6-18 months

Weak direct network effects; indirect data network effect as more scans improve AI model accuracy, creating modest but real competitive moat over time

-32.5% Return on Assets (Negative equity)

Moderate resilience; cardiac diagnostics have clinical urgency but elective procedure deferral in recessions reduces scan volumes and revenue directly

Hospital cardiology and radiology departments (large academic medical centers and integrated health systems) represent primary buyers; top 10 IDNs likely >40% revenue

Interventional cardiologists and referring physicians as clinical champions; payers (CMS, commercial insurers) as indirect but critical reimbursement gatekeepers

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

2.9% CapEx / Revenue (Low-CapEx Asset-Light)

0001464521

HTFL